Literature DB >> 23669067

FACS binding assay for analysing GDNF interactions.

Luís Quintino1, Aurélie Baudet, Jonas Larsson, Cecilia Lundberg.   

Abstract

Glial cell-line derived neurotrophic factor (GDNF) is a secreted protein with great therapeutic potential. However, in order to analyse the interactions between GDNF and its receptors, researchers have been mostly dependent of radioactive binding assays. We developed a FACS-based binding assay for GDNF as an alternative to current methods. We demonstrated that the FACS-based assay using TGW cells allowed readily detection of GDNF binding and displacement to endogenous receptors. The dissociation constant and half maximal inhibitory concentration obtained were comparable to other studies using standard binding assays. Overall, this FACS-based, simple to perform and adaptable to high throughput setup, provides a safer and reliable alternative to radioactive methods.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  293T cells expressing GFRα1; 293T-GFR1; Binding assay; DOL; Degree of labelling; FACS; Fluorescent-activated cell sorting; G-CSF; GDNF; GDNF Family receptor alpha; GDNF conjugated with Alexa 488; GDNF(488); GFRα; Glial cell-line derived neurotrophic factor; granulocyte-colony stimulating factor

Mesh:

Substances:

Year:  2013        PMID: 23669067     DOI: 10.1016/j.jneumeth.2013.04.006

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  2 in total

1.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

2.  Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer.

Authors:  Darryl T Martin; Jill M Steinbach; Jingchun Liu; Shogo Shimizu; Hristos Z Kaimakliotis; Marcia A Wheeler; Adam B Hittelman; W Mark Saltzman; Robert M Weiss
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.